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Abstract 
The vaginal route is increasingly being considered for both local and systemic delivery of drugs, 
especially those unsuitable for oral administration. One of the opportunities offered by this route but 
yet to be fully utilized is the administration of microbicides. Microbicides have an unprecedented 
potential for mitigating the global burden from HIV infection as heterosexual contact accounts for most 
of the new infections occurring in sub-Saharan Africa, the region with the highest prevalent rates. 
Decades of efforts and massive investment of resources into developing an ideal microbicide have 
resulted in disappointing outcomes, as attested by several clinical trials assessing the suitability of those 
formulated so far. The highly complex and multi-level biochemical interactions that must occur among 
the virus, host cells and the drug for transmission to be halted means that less a sophisticated approach 
to formulating a microbicide e.g. conventional gels, etc. may have to give way for a different 
formulation approach. Nanotechnology has been identified to offer prospects for fabricating structures 
with high capability of disrupting HIV transmission.  
In this review, predominant challenges seen in microbicide development have been highlighted and 
possible ways of surmounting them suggested. Furthermore, formulations utilising some of these highly 
promising nanostructures such as liposomes, nanofibres and nanoparticles have been discussed. A 
perspective on how a tripartite collaboration among governments and their agencies, the pharmaceutical 
industry and academic scientists to facilitate the development of an ideal microbicide in a timely manner 
has also been deliberated briefly.   
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1. Introduction 
1.1 Vagina anatomy and adaptation for drug delivery 
The human vagina has been a route for administering drugs since ancient times (Hussain and Ahsan, 
2005). However, it was mainly used to deliver drugs for local effects until 1918 when it was found to 
be capable of systemic delivery (Macht, 1918). Since then, this route of administration has gained 
relevance as a viable option for drug delivery in modern medicine. Several classes of medicine are 
currently approved for vaginal application.  In this era of increasing discovery of poorly soluble new 
chemical entities (NCE), protein based therapeutics and other biologics, vaginal delivery of drugs for 
systemic use is increasingly being considered as an alternative to oral administration (Baloglu, Bernkop-
Schnürch, Karavana and Senyigit, 2009; Bassi and Kaur, 2012; Hussain and Ahsan, 2005). 
Furthermore, where a local effect or less invasive route of administration is desirable, vaginal delivery 
of a drug presents a more viable therapeutic strategy than many other routes (Fallowfield et al., 2006). 
The human vagina is a fibromuscular S-shaped canal, between 6 and 12 cm long and connecting the 
cervix to the vulva vestibule (Neves, Palmeira‐de‐Oliveira, Palmeira‐de‐Oliveira, Rodrigues and 
Sarmento, 2014). The upper portion is wider and almost horizontal when in upright posture and the 
lower part is convex in shape (Funt, Thompson and Birch, 1978). This anatomical positioning and shape 
contributes to the retention of objects inserted deep into the vagina, thus making it a suitable destination 
for application of materials such as dosage forms and medical devices (Barnhart, Pretorius and 
Malamud, 2004). In addition, the increased surface area of the vagina arising from several rugae and 
extensive vascularisation facilitating access to major blood vessels and organs like the inferior vena 
cava and uterus offer immense potential for systemic drug delivery (De Ziegler, Bulletti, De Monstier 
and Jääskeläinen, 1997; Katz, Lentz, Lobo and Gershenson, 2007). 
 
 
Figure. 1: Types of vaginal dosage forms presently in use. 
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Some advanced methods of drug delivery to the vagina has recently been reported. Coconut-oil core 
cationic nanocapsule of clotrimazole prepared from Eudragit® RS100 polymer has been reported to 
offer prolonged delivery of the antifungal drug to the vagina, offering better antifungal activity against 
Candida sp. compared to ordinary clotrimazole creams (Santos et al., 2014). In another example, 
Paclitaxel delivered as mucus-penetrating nanoparticles made form poly(lactic- co -glycolic acid) was 
reported as being more effective in suppressing tumour growth and prolonging the median survival in 
animal models (Yang et al., 2014).  
Apart from the possibility of being useful for the systemic delivery of some drugs, the vaginal route 
offer prospects for other drug delivery strategies.  
 
Figure 2: Silicone elastomer vaginal ring and an inserted ring in a female reproductive tract (Schopflin, Laudahn, Muhe, 
Hartmann and Windt, 1977) 
 
For instance the vaginal structure and environment can be adapted for long term delivery of some 
medications, e.g. contraceptives, where strict adherence is required for the desired effect. Vaginal rings 
(Schopflin, Laudahn, Muhe, Hartmann and Windt, 1977) for delivering contraceptives over several 
months have been shown to maintain constant serum levels of the drug, thus offering an effective 
solution to problems often arising from nonadherence to oral contraceptives such as through missed 
dose (Potter, Oakley, de Leon-Wong and Cañamar, 1996). This also takes away the daily burden of 
taking pills orally and therefore a more convenient approach. Adverse drug effects such as 
gastrointestinal disturbances, typically occurring after oral administration of a drug can be mitigated by 
delivering via the vaginal route. For instance, gastrointestinal disturbances resulting from the oral 
administration of bromocriptine were drastically reduced when give vaginally, in addition to improved 
bioavailability (Vermesh, Fossum and Kletzky, 1988). Vaginal route is also particularly helpful for 
systemic delivery of drug susceptible to extensive hepatic metabolism or when intestinal absorption 
capacity is impaired and also helpful for avoiding possible drug-drug or drug-food interactions in the 
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gastrointestinal system (Tozer, 1996). In a more recent study, vaginal delivery of subunit vaccines was 
confirmed to induce better immunity when compared to rectal or intranasal delivery (Lowry, 2015) 
Notwithstanding the promising prospects of optimized pharmacotherapy offered by this route, there 
remains challenges. Perhaps the first and most obvious disadvantage of vagina as a route of drug 
administration is its gender specificity (Neves et al., 2014). Drug delivery through the vagina is only 
possible for women. The other challenges associated with vaginal delivery of drug mainly involves 
cultural perceptions about insertions into the vagina, perceived interference with personal hygiene and 
possible interference with coitus in sexually active women. Likely local irritations and widely varying 
pharmacokinetics following vaginal administration of drugs also pose some challenges in this route of 
administration (Srikrishna and Cardozo, 2013).    
 
1.2 HIV transmission and strategies for prevention 
Heterosexual intercourse is among the most common routes for HIV transmission and prevention 
remains the most effective way of containing the growing epidemic (De Cock, Jaffe and Curran, 2012; 
Weller and Davis, 2003). In sub-Saharan Africa, where new HIV infections are nearly two-thirds of all 
global incidences, heterosexual intercourse  has been identified as the main epidemic’s driving force 
(UNAIDS, 2008). Considering the impact of heterosexual transmission of HIV, and the fact that 
prevention still remains the most effective strategy for confronting this disease, an ideal microbicide 
delivered vaginally has been identified to have immense potential for reducing new HIV infections by 
preventing heterosexual transmission (Balzarini and Van Damme, 2007).  
 
 
Figure 3: Sources of HIV transmission in Kenya, a sub-Saharan African country where heterosexual transmission accounts for 
more than half of all HIV infections (Gelmon, 2009) 
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1.3 Outline of review  
In this review, the challenges, opportunities and the current state of affairs with the development of a 
suitable microbicide are discussed. The shift towards nanotechnology, exploring the possibility of 
utilising nanostructures either as carrier systems for effective delivery of highly active antiretroviral 
drugs into target areas for optimal performance or harnessing their inherent antiviral activity has been 
elaborated. Additionally, this review looks into the requirements, concepts and models which ought to 
be in place to ensure that laboratory based experiments are translated into clinical usefulness. 
 
2. Microbicides 
A microbicide is defined as an anti-infective formulation intended for vaginal or rectal application by 
individuals to protect themselves and their sexual partners against HIV and other sexually transmitted 
infections. Microbicides are typically self-administered topical preparations (Garg, Nuttall and 
Romano, 2009; Stone, 2010). An effective and affordable microbicide formulation is increasingly being 
considered by global health experts as crucial to a strategy for reduction of HIV transmission.  
 
Figure 4: Characteristics of an ideal microbicide (Balzarini and Van Damme, 2007; Singh, Garg, Rath and Goyal, 2014) 
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Whereas other preventive strategies such as condom use have been in existence for many decades, 
microbicide use is considered as the most effective approach to HIV prevention where the power and 
choice to initiate its use totally depend on women, thus empowering them to protect themselves and 
their partners. For a global-wide implementation of a preventive scheme based on microbicide usage, 
an availability of a wide range of formulations to meet the diverse expectations of different populations 
with widely varying socio-cultural attitudes to sex is vital. Outcomes from trials of microbicide 
formulations developed over the last decade have not been too encouraging (Grant et al., 2008).  Issues 
relating to the performance and safety of conventional formulations like gels, physical presentation and 
acceptability are among the tremendous challenges encountered in our quest to develop an ideal 
microbicide.   
It is now clear that an effective product against HIV transmission, more so a kind that could be applied 
externally and at the discretion of women is urgently needed if we are to contain the threat posed by 
new HIV infections. Therefore investigating a product already licenced for vaginal application with a 
potential for disrupting the integrity of the viral structure upon contact appeared to be a prudent and 
faster route to obtaining a microbicide. A fast-track approach led to extensive trials on Nonoxynol-9, a 
surfactant capable of disrupting the membrane structure of spermatozoa and with similar effects on HIV 
lipid membrane and many other pathogens that are sexually transmitted (Stone, 2002). The hopes with 
Nonoxynol-9 as possible transmission barrier to HIV was halted when a review of numerous trials by 
WHO, particularly on the potential benefits and safety, concluded that this surfactant was not a good 
candidate for the topical prevention of HIV (WHO, 2002). It was observed that frequent application of 
Nonoxynol-9 specifically resulted in adverse effects including irritation, inflammation, tissue 
infiltration by immune cells and massive disruption of the vaginal flora (Beer et al., 2006). This actually 
resulted in a higher rate of infection among women on this trial product than the placebo group (Van 
Damme et al., 2002).   This conclusion has heightened the urgency for a suitable topical medication 
against HIV transmission. The intensified search for this preventive medication has taken a wide and 
varied approach. It has been reported that though no product is commercially available yet, over 40 
candidates are being investigated with a significant proportion in clinical trials (Li, Zaveri, Ziegler and 
Hayes, 2013). The active pharmaceutical ingredients (API) employed include, nucleoside reverse 
transcriptase inhibitors (NRTIs) non-nucleoside reverse transcriptase inhibitors NNRTIs and 
genetically engineered inhibitor-expressing bacteria (Klasse, Shattock and Moore, 2006). Much as there 
appear to be several active ingredients and material effective for topically preventing transmission of 
HIV, the complexity of the mucosa environment through which most infections are transmitted i.e. the 
vaginal and/or rectal region and processes involved for the virus to move through several layers to infect 
target cells means a herculean formulation challenge lies between humans and a microbicide effective 
in combating HIV transmission. 
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2.1 HIV transmission and microbicide activity 
There are still some uncertainties and dissenting views among scientists on activities leading to HIV 
transmission, i.e. details pertaining to cells and receptors in the genital environment necessary for 
transmission to occur, the influence of vaginal biological factors on transmission and the inherent host 
activities that protect against or facilitate processes leading to the viral infection (Dhawan and Mayer, 
2006; Shattock and Moore, 2003). In recent times however, there has been a considerable increase in 
our understanding of viral-host interaction underlying HIV transmission, especially through the 
mucosa, thus equipping us with the needed information for developing better strategies against the 
spread of HIV infections (Shaw and Hunter, 2012; Tebit, Ndembi, Weinberg and Quiñones-Mateu, 
2012; Wu, 2008).  
There are multiple infection pathways through which HIV transmission occur. For instance in the 
genital tract, the virus can proceed through the several layered stratified vaginal epithelium or the single 
layer cervical columnar epithelium layer (Pope and Haase, 2003). Transcytosis along a vesicular 
pathways has been established as one of the main mechanism by which HIV-1 virus cross intact barriers 
to infect host cells beneath the tissue (Bomsel, 1997).  
 
 
Figure 5: Potential target sites and mode of action for microbicides in preventing HIV transmission.  
8 
 
It is now know that viral infections including HIV occur through two main transmission modes – as cell 
free virion from an infected cell that moves through the extracellular environment by diffusion to 
encounter and infect a target cell or by direct cell-to-cell infection after a cell infected with the virus 
encounters a target cell (Anderson, 2014). It has been established through in vitro studies that cell-to-
cell transmission of HIV can be up to or sometimes even more than 1000 times more efficient than cell-
free transmission (Chen, Hübner, Spinelli and Chen, 2007; Mazurov, Ilinskaya, Heidecker, Lloyd and 
Derse, 2010). Once in the sub-mucosa area, the virion or virus can then infect CD4+ T-cells, 
macrophages and dendritic cells by attaching its envelope gp120 protein to surface proteins on these 
cells (Patterson et al., 1998; Veazey, Marx and Lackner, 2003).Subsequently, replication cycle of the 
virus in host cells occurs. An ideal microbicide would therefore be expected to combine activities 
against transcytosis, attachment and intracellular replication and hence a combination of different drugs 
may have to be administered to offer an effective and wide spectrum of protection.   
The various stages of HIV transmission, up until viral replication in host cells, i.e. viral passage through 
various epithelia in the genital area, fusion of virus with host cells, viral replication, are principally the 
targets for microbicides currently in development or trial. Currently available active agents to be 
developed into microbicides and their respective sites and modes of action, as summarized in table 1, 
come in such diverse characteristics and hence require different formulation approaches to ensure their 
applicability and efficacy.  
 
Table1: Target sites, mode of action and agents for the prevention of HIV transmission (Balzarini and Van Damme, 2007)  
Area of activity Mechanism of action Microbicide agent 
Mucosa environment e.g. 
vaginal, rectal 
Direct inactivation of virus 
Maintaining natural vaginal environment for 
innate immunity against infections 
Physical barrier to transmission  
Detergents or surfactants 
Lactobacilli, buffering agents 
 
Topical formulations e.g. gels 
Tissue/cell surface Preventing virus from entering target cells by 
interfering with host cell receptor/virus 
interactions  
Monoclonal antibodies 
Small molecule inhibitors 
 
Virus surface HIV entry inhibition by targeting viral 
envelope fusion onto host cells 
Polyanions 
Carbohydrate binding agents 
Monoclonal antibodies 
Inside the host cell Interfering with viral replication cycle. 
Inhibition of virus-encoded reverse 
transcriptase (RT) or integrase  
Nucleotide RT inhibitor 
Non-nucleoside RT inhibitor 
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Table 2 shows some of the formulations presently in clinical trial. There are still opportunities to enrich 
the pipeline of effective microbicides and hence the advocacy for considering interventions from 
nanotechnology to offer some solutions to the myriad of challenges encountered in creating these 
systems. 
 
Table 2: Some recent microbicide formulations clinical trials [Source: www.ipmglobal.org; http://www.mtnstopshiv.org/] 
Trial Name  Phase  Start Date  Countries  Population  Candidate(s)  Status  Expected 
Completion 
Date  
FACTS 002  
An adolescent safety study 
designed to test the safety and 
acceptability of tenofovir gel in 
16- and 17-year-old South 
African young women 
II  July 1, 2015  South Africa  Women  1% Tenofovir 
gel  
Ongoing  December 
2016  
A13-128  
Safety of the TFV/LNGa, and 
TFV-only intravaginal rings 
pharmacokinetics of TFV and 
LNG acceptability of 
intravaginal rings 
 
I  November 30, 
2014  
United States 
of America, 
Dominican 
Republic  
Women  TFV ring, 
TFV/LNG 
ring  
Completed  November 
2015  
MTN 017  
Assess the safety, acceptability, 
systemic and local absorption, 
and adherence of reduced 
glycerine tenofovir gel applied 
rectally 
II  September 30, 
2013  
Thailand, 
South Africa, 
United States 
of America, 
Puerto Rico, 
Peru  
Transgender, 
HIV negative, 
MSM c  
Reduced 
Glycerine 1% 
Tenofovir 
Gel, 
TDF/FTC b 
(Truvada)  
Completed June 2016  
IPM 027 (The Ring Study)  
To assess the safety and 
efficacy of a silicone elastomer 
vaginal matrix ring 
III  April 30, 2012  South Africa, 
Uganda  
Women  Dapivirine 
Ring  
Ongoing  December 
2016  
 
a TFV/LNG = Tenofovir / levonorgestrel; b TDF/FTC =Tenofovir disoproxil / emtricitabine; c MSM = Men who 
have sex with men 
 
2.2 Formulation of microbicides 
The foremost challenge encountered in microbicide formulation is to get a drug capable of navigating 
the complex tissue of the cervico-vaginal lumen to provide effective protection. In order to reduce the 
possibility of HIV disseminating beyond microbicide’s reach and action, a formulation with substantial 
mucosal permeating action is crucial (Hladik and Doncel, 2010). Therefore materials with structural 
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characteristics flexible enough to be adapted for far reaching impact will be crucial to design of an 
effective microbicide. Furthermore, the routine physico-chemical compatibilities between active 
ingredients and excipients needs to be established. Of particular importance is the drug stability in 
aqueous state, as the site of application, the vaginal environment is predominantly aqueous (Garg et al., 
2009). Combination therapy is well accepted in managing HIV/AIDS infections, as it has been 
confirmed to offer better treatment outcomes than monotherapy (Lange, 1995; Moore and Chaisson, 
1999). Therefore, a strategy which combines multiple active ingredients may be worth considering for 
development of microbicides. In addition to monitoring compatibility issues that may arise from 
interaction among the different active ingredients combined, reliable models and methods ought to be 
designed to effectively assess likely additive, synergistic or antagonistic interactions that may occur. 
Another challenge an effective microbicide formulation ought to withstand is the rapid pH changes that 
occur in the cervico-vaginal environment during intercourse. There is an immediate transition from pH 
approximately 4.0 to around 7.0 following release of semen. For effective protection against HIV 
transmission, there ought to be a microbicide robust enough to remain effective through rapid 
environmental changes, as there are strong indications that significant departure from the normal pH 
levels in this environment can affect the efficacy of most microbicides (Neurath, Strick and Li, 2006). 
In order to achieve such a robust formulation, a reliable model capable of establishing that efficacy and 
performance of a microbicide seen at the in vitro stage of formulation development can be realized in 
vivo, particularly in an environment combining seminal fluid, cervico-vaginal secretions and mucus 
which is typical of challenging situations where microbicides are likely to lose their efficacy (Turpin, 
2011).  Finally, the formulation strategy would have to address the critical question of product 
acceptability as an outstanding formulation would require high acceptance for it to ensure usage. High 
acceptability will guarantee appreciable level of adherence. With regard to dosage forms for vaginal 
application, there is a precedent that can inform decisions to arrive at a product likely to be well 
patronized (Vermani and Garg, 2000). Ease of applicability, dose frequency, physical state and 
appearance of drug are some of the key factors that determine how well these formulations are accepted.   
 
2.3 Acceptability of microbicides  
A compelling reason for advocating microbicide use as an effective strategy and the future for HIV 
transmission reduction is the fact that its use is largely woman initiated and therefore an outstanding 
opportunity to empower women with more options for safer sex. For instance in a recent survey on 
microbicide adherence, it was confirmed that disclosure of microbicide use by women to male partners 
significantly improved adherence thus establishing the role of male partners in successful 
implementation of a microbicide strategy (Mngadi et al., 2014). Beyond these considerations, factors 
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generally dictating acceptability of any drug formulation i.e. ease and convenience of use, dosage 
frequency, anticipated adverse reaction etc. ought to be factored into the pre-formulation planning.   
 
Figure 6: Factors that can influence microbicide acceptability (Balzarini and Van Damme, 2007; Singh et al., 2014)  
 
Furthermore, as with most products relating to sexual lifestyle, the demographics and socio-cultural 
influences among the target market for a particular microbicide formulation ought to be accommodated 
in order to get a product with wide acceptability. In a study assessing acceptance rates in populations 
with different cultural influences, it was found that women’s perception of subjects like vaginal 
cleanliness e.g. leakages associated with menstruation and negative or positive associations with vaginal 
douches resulted in different perception and acceptability of the same gel formulation in different 
groups (Giguere et al., 2012) 
The numerous requirements to be met in order to produce a microbicide formulation for wider 
acceptability imply that several options including a variety of materials for fabrication is needed for 
different microbicide forms suiting different populations. An emerging class of materials, 
nanostructures, due to their high degree of structural flexibility and surface properties, when optimized 
to suite could be a positive addition to the stock of materials for an effective microbicide formulation. 
In populations with negative perception on vaginal leakage, for instance, where gel formulations are 
unlikely to be widely accepted and used, nanofibre could be an alternative material for forming dosage 
forms capable of addressing issues of leakage. Further suggestions and reasons why nanomaterials may 
drive the future of microbicide formulation are expounded. 
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2.4 Present state of microbicide development 
The majority of microbicide which has been or currently in clinical trials (some examples shown in 
table 2) are conventional semi-solid formulations, particularly in the gels designed to effectively deliver 
a single dose of an antiviral agent at a time (Di Fabio et al., 2003; Ndesendo et al., 2008; Stone, 2002; 
Van Herrewege et al., 2004). Several of these formulations have failed to demonstrate adequate 
efficacy, safety and tolerability, thus prompting a re-evaluation of the current development paradigm 
(Karim and Baxter, 2014; Hendrix, Cao and Fuchs, 2009). Indeed the focus on formulating an effective 
microbicide for the prevention of HIV transmission is gradually expanding from earlier concepts that 
centred on gel and cream formulations to include such forms as films and fast dissolving solids (Rohan, 
Devlin and Yang, 2014). However, there is still more room for improving upon the existing range of 
vaginal dosage forms intended for the delivery of microbicides. Some of the key challenges identified 
during trial of these formulations, including disruption or inflammation of mucosal epithelium, effect 
of pH conditions and proteolytic enzyme action in the genital tract, inadequate delivery of active drug 
to target sites due to poor retention and inconvenience associated with use frequency of application are 
likely to be surmounted through strategies utilising nanotechnology applications (D'Cruz and Uckun, 
2014).  
Further into this review, opportunities presented by nanotechnology, i.e. the possibility of utilising the 
unique physical and structural properties of nanostructures such as nanofibres, liposomes, dendrimers 
and nanoparticles for addressing some of the specific issues seen in the current stock of microbicides 
are discussed. Nanotech inspired approaches to formulating drugs and medical devices has proved to 
be successful in some therapeutic areas like cancer management. When extensively researched and 
adequately applied, these same technologies could be resourceful in the development of the next 
generation of microbicides. 
 
3. Microbicide development through nanotechnology 
An effective microbicide is not yet available for use and despite tremendous efforts and resources 
invested in the development of an ideal microbicide for over three decades, outcomes from both 
preclinical and clinical trials on existing formulations have been overall quite disappointing (Karim, 
2010). The approach to developing microbicides, up until recently has been mainly by conventional 
formulation methods such as gel formulation and this appear to contribute to the numerous issues 
identified in the current pipeline of microbicides (Garg et al., 2010). Many of the challenges seen in 
current formulations being considered, such as inadequacy in targeting and delivering active drug into 
sites required for drug action and stability of drug in formulations could be surmounted by exploring 
options in nanotechnology, an area capable of delivering better targeting, flexibility for combination 
13 
 
therapy and more desirable pharmacokinetic profiles, as seen for instance in the area of cancer 
management (Sharma and Garg, 2010; Singh et al., 2014). 
The antiretroviral drug tenofovir, for instance could be delivered as nanofibre based dosage form with 
enhanced surface properties for adequate mucosal contact to facilitate sustained release over extended 
periods. These nanofibres may be generated from a homogeneous mixture of the active drug at required 
concentration and polymers capable of yielding desired physical and release properties in a safe solvent 
system. The resulting fibres could offer many possibilities of formulating solid dosage forms in varying 
geometric forms to make them fit for purpose.  
A variety of polymers are known to act against viral transmission on their own. For instance some 
anionic polymers are thought to adhere to viral envelopes through their negative charges and thereby 
blocking viral entry into target cells (Balzarini and Van Damme, 2007). Though higher concentrations 
of these polymers are required for this antiviral activity to occur, the extremely low general toxicity of 
these materials imply that employing optimal formulation methods and conditions could help realize 
the therapeutic benefits of these materials. A careful selection and combination of polymers from a wide 
range of polyanionic compounds are likely to work in synergy with antiviral agents like tenofovir for 
potentiated activity against transmission of HIV. Specifically, sulphated polysaccharides such as 
dextrin, dextran and cellulose sulphates, aliphatic and aromatic carboxylates such as carbomer 974P 
and some aryl sulphonates are all anionic polymers whose antiviral potential have long been established 
(Howett and Kuhl, 2005; Pauwels and De Clercq, 1996). Some polyanionic dendrimers are also known 
to have some inherent antiviral activity (Ross and George, 1995). Carboxylated fullerene-based 
dendrimers for instance have been shown to offer antiviral activities by inhibiting viral protease and 
reverse transcriptase in acutely HIV infected primary human lymphocytes (Schinazi, Brettreich and 
Hirsch, 2001).     
Through nanotechnology, microbicide formulations capable of combining the therapeutic effect of their 
carrier material such as those made of polyanionic materials and an active drug such as tenofovir, a 
nucleotide reverse transcriptase inhibitors which works by disrupting intracellular viral replication 
could be developed to offer adequate protection against HIV infection. Microbicides combining 
multiple therapeutic agents are confirmed to be safer and more effective in preventing HIV transmission 
(Dang et al., 2014; Gantlett, Weber and Sattentau, 2007; Vacas-Córdoba et al., 2014). Studies have 
confirmed the synergistic benefit of combined antiviral action occurring at different stages of the HIV 
replication simultaneously in the form of multiple-fold transmission reduction and appreciable potency 
even at lower doses which improved the safety profile of these combinations (Liu, Lu, Neurath and 
Jiang, 2005; Pirrone, Thakkar, Jacobson, Wigdahl and Krebs, 2011; Sepúlveda-Crespo et al., 2014).  
Nanotechnology inspired formulations including liposomes, dendrimers, nanofibres and nanoparticles 
are known for their performance, versatility and flexibility and therefore offering immense 
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opportunities for tailoring their shapes and structures for specific drug delivery functions 
(Venkataraman et al., 2011). Nanotechnology could also be instrumental in the development of 
microbicides with optimal release profiles and whose activities are derived from multiple active 
ingredients (combination therapy).  
 
3.1 Prospects for combination therapy 
Nanotechnology is widely being used in the design of novel systems capable of delivering multiple 
drugs from a single unit (Parhi, Mohanty and Sahoo, 2012; Tang, Lei, Guo and Huang, 2010). These 
new technologies are being used to create platforms for effective combination pharmacotherapy, 
especially in the area of cancer management. Some of these nanotech strategies that has been so valuable 
in other areas of pharmacotherapy could be adapted for the development of practically useful 
microbicides. A microbicide, for example addressing multiple issues such as maintaining ideal 
environment in the vagina and at the same time preventing viral infection at different stages of an 
invasion would be a breakthrough.   There are possibilities to include adjuvant into microbicide 
formulations in order to achieve multi-level protection against HIV infection. Maintaining a suitable 
level of acidity (pH) in the cervico-vaginal environment for instance is known to be crucial for immunity 
against HIV and other pathogens (Balzarini and Van Damme, 2007; Olmsted et al., 2005). However, 
during sex, when microbicides is expected to offer protection against HIV transmission, the slightly 
alkaline semen is capable of diminishing this level of acidity and thereby significantly reducing this 
natural defence mechanism (Baron, Singh, Chopra, Coppenhaver and Pan, 2000). Furthermore, a 
microbicide formulated to be effective in a particular pH environment could lose some activity when a 
sudden change in pH occurs. The co-administration of an adjuvant with an appreciable buffering 
capacity could potentiate the overall protection conferred by the microbicide. The unique structure of 
dendrimers, for instance, could be developed to contain functional groups capable of acting as pH 
buffers within its highly branched network alongside conjugates of its peripheral molecules with 
antiviral groups could form the base unit of an effective microbicide. Nanofibre based dosage form 
made from several discrete units of fibre each encapsulating either an API or an adjuvant such as pH 
buffer could also make a desirable microbicide. Co-application of probiotics with microbicides have 
been suggested to help re-acidify and maintain the commensal vaginal flora for optimal protection and 
indeed some buffering agent formulations such as BufferGel (ReProtect; Baltimore, MD, USA) are 
already in clinical trials for vaginal defence mechanism (Balzarini and Van Damme, 2007; Olmsted et 
al., 2005).  
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3.2 Modulating drug release 
Nanotechnology continues to make a significant contribution to the development of new and more 
effective drug delivery systems (Shi, Votruba, Farokhzad and Langer, 2010). Microbicides developed 
through nanotechnology could benefit from improved solubility of hydrophobic drugs, controlled 
release of drugs and better immunogenicity and safety profile.  
The fact that a wide range of material can be used in developing these nanocarriers offers opportunities 
for extensive manipulations to obtain a microbicide formulation with a desired drug release kinetics. In 
systems utilising nanofibres for instance, there have and continue to be numerous studies exploring their 
prospects of modulating drug release. (Singh et al., 2014; Son, Kim and Yoo, 2014; Verreck et al., 
2003). Known to degrade in biological systems slowly, polycaprolactone for instance, has been used to 
achieve slow and steady release of tetracycline over periods up to 200 hours (Karuppuswamy, Reddy 
Venugopal, Navaneethan, Luwang Laiva and Ramakrishna, 2015). Getting the release kinetics of drug 
from microbicide is crucial to the overall usefulness and acceptability. Depending on the prevalent 
socio-cultural attitude towards sex, microbicide use may not be widely accepted if it ought to be applied 
shortly before an encounter as the presence of a male partner could discourage this. In other situations, 
prolonged microbicide action may be desirable as multiple sexual encounters over lengthy periods are 
likely but frequent application of an intervention impractical. In these two likely scenarios, extended 
release microbicide formulations would be required for effective protection against HIV infection. 
Polyethylene oxide (PEO) and polycaprolactone (PCL) are polymers readily available and routinely 
used in various applications including drug delivery. Whereas PEO is soluble in water and yields fibres 
which are even more rapidly soluble in aqueous media (Row, Sheskey and Quinn, 2009) PCL slowly 
degrades, usually  by hydrolysis throughout the polymer matrix after water has gradually penetrated the 
entire polymer bulk (Woodruff and Hutmacher, 2010). Using an appropriate solvent system, suitable 
amounts of PCL could be used to modulate drug release from PEO nanofibres by modifying their overall 
solubility in aqueous media. Microbicides based on slowly degrading nanofibres could be a good 
balance between ultra-long acting vaginal rings and rapidly eliminated gel based formulations. The 
possibility of making nanofibres from different polymers in order to confer some specific characteristic 
to the fibres have been demonstrated (Brako, Raimi-Abraham, Mahalingam, Craig and Edirisinghe, 
2015).   
Dendrimer complexes and conjugates have been used to optimize drug release in a number of 
formulations (Nanjwade, Bechra, Derkar, Manvi and Nanjwade, 2009). A dendritic formulation of 
Flurbiprofen was also used to achieve extended release of the drug, allowing drug release over periods 
up to three times more than what is usually seen in free drug formulations (Asthana, Chauhan, Diwan 
and Jain, 2005). Drug release from gel formulations has been prolonged and made to obey zero-order 
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kinetics by first encapsulating the active ingredient in liposomes (Glavas-Dodov, Goracinova, 
Mladenovska and Fredro-Kumbaradzi, 2002).  
 
3.3 Nanostructures currently being explored for development of microbicides 
3.3.1 Nanofibre based microbicide 
A nanofibre typically has two similar external dimensions (making up the cross-sectional area) within 
the nanoscale, and the third dimension, usually the length, significantly larger (Glavas-Dodov et al., 
2002). Nanofibres are currently produced by widely varying methods including molecular self-
assembly, thermally induced phase separation and fibre spinning (Luo, Stoyanov, Stride, Pelan and 
Edirisinghe, 2012). Of all these methods, fibre spinning, a term used to describe the various methods of 
fibre formation by extrusion through a spinneret appears to be the most widely used method. 
Electrospinning and centrifugal spinning are two of fibre spinning methods commonly used. 
Notwithstanding, novel gyration methods such as pressurised gyration are coming to the forefront as 
this has demonstrated potential of upscaling production to meet commercial demands for various 
applications (Brako, Raimi-Abraham, Mahalingam, Craig and Edirisinghe, 2015; Mahalingam and 
Edirisinghe, 2013; Xu et al., 2015) 
Nanofibres, depending on constituent materials and conditions of fabrication could exhibit widely 
varying morphology and structural properties. However, features such as high surface area to volume 
ratio and well defined porosity are typical of nanofibres and have often been reasons why they are 
desirable for drug delivery applications (Pillay et al., 2013). High surface area per unit mass of 
nanofibres could be harnessed to overcome solubility issues seen in many APIs e.g. ibuprofen, usually 
by combining them with hydrophilic materials of nanofibres (Williams et al., 2012). In addition, 
controlling the matrix properties such as fibre diameter and porosity by manipulating fabrication 
parameters allows for the incorporation of delicate molecules such as proteins, antibodies and DNA 
into nanofibre constructs such as meshes for site-specific delivery in the body (Pillay et al., 2013). 
Significantly higher encapsulation efficiency is attainable when active ingredients are incorporated into 
nanofibres (Liao, Chew and Leong, 2006; Xie and Wang, 2006). Achieving drug loading in excess of 
90% offers the possibility of designing highly efficient delivery systems with fewer additives and 
excipients. This ultimately enhances the safety profile of the formulation since unwanted materials, 
which have to be metabolized and eliminated are already in minimal quantities. Drug delivery systems 
utilising polymeric nanofibres as basic units can be designed as a multi-compartment assembly 
delivering different active drugs from a single unit. Basically, multiple APIs may be encapsulated in 
different nanofibres and combined to be presented as one unit. The multi-targeted approach is a viable 
option since the individual encapsulations prevent the active ingredients from interacting among 
themselves regardless of their proximities, until onset of drug action. Finally, the potential of 
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modulating drug release from nanofibre systems by varying their material constituents makes these 
structures attractive for drug delivery (Kenawy, Abdel-Hay, El-Newehy and Wnek, 2009). Considering 
the wide array of suitable materials available for making nanofibres, several possible combinations may 
be selected for a specific release kinetic desired. The starting point for most nanofibre production 
requires the materials to be in solution or melt. Therefore most materials, especially polymers, once 
converted to the suitable liquid state and such properties as viscosity and surface tension optimized may 
be transformed into nanofibres by the appropriate method. This feature of making nanofibres enable the 
accommodation of a wide range of materials thereby enhancing the prospects of manipulating release 
kinetics through choice of materials. 
Some of these exceptional qualities of nanofibres, if harnessed, effectively could be useful for the design 
of microbicide highly suitable for preventing HIV transmission. The final geometry of microbicide 
developed from nanofibres will be crucial both to their acceptability and drug delivery performance. 
Dosage forms intended for insertion into the vagina vary in shape from globular or ovoid such as round 
or long oval through modified conical shapes like bullet to cylindrical forms including tampons (Hanan 
and Durgin, 2014). A correlation between shape of vaginal suppositories and willingness to try or use 
the product has been established (Li, Zaveri, Ziegler and Hayes, 2013). 
 
 
Figure 7: a) Nanofibres produced by pressurized gyration method (Mahalingam and Edirisinghe, 2013) and b) revealing 
porosity that can be utilized for optimal drug delivery  
 
Presenting the shape of a nanofibre based microbicide suppository in a shape widely accepted by 
anticipated users is therefore fundamental to the overall success of any such microbicide. A few 
microbicides formulated entirely from nanofibres have been developed and trialled with some 
encouraging outcomes reported. Maraviroc eluting nanofibres made from polyethylene oxide and poly 
lactic acid polymers have been demonstrated to be affective against HIV-1 in vitro (Ball, Krogstad, 
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Chaowanachan and Woodrow, 2012). Furthermore, a nanofibre based delivery system capable of drug 
loading of up to 28 wt. % and hence able to deliver high doses of the potent antiretroviral maraviroc 
rapidly has been developed (Ball and Woodrow, 2014). This formulation is reported to be a superior 
alternative to previous gel formulations of the same antiretroviral, where the drug appears either 
insoluble or when made to be completely dissolved, appear too bulky, at minimum drug loading of 3.3 
wt. % required to inhibit any retroviral activity (Malcolm et al., 2013). Scientist behind these antiviral 
eluting nanofibres (Ball and Woodrow, 2014) have been quoted as suggesting the development of 
nanofibre based tampons offering protection against HIV transmission when applied shortly before 
intercourse (Huffington Post, 2014). When successfully developed, trialled and confirmed as effective 
for preventing HIV transmission, this would confirm the utility of nanofibres as alternate approach to 
microbicide formulation. Additionally, it will inspire further research into the relatively unexplored area 
of harnessing the immense benefits of nanofibre structures for the superior performance of systems 
capable of more efficient delivery of drugs through mucosa membranes in general.  
 
3.3.2 Polymeric nanoparticles for microbicides 
Nanoparticle for drug delivery has been broadly defined to include particulate systems with mean 
diameter between 50 and 1000nm (zur Mühlen, Schwarz and Mehnert, 1998). Polymeric nanoparticles 
(NP) are typically the result of spontaneous self-assembling of amphiphilic polymers when dispersed 
in an aqueous medium (Uchegbu, Schätzlein, Cheng and Lalatsa, 2013). The self-assembly is usually 
driven by methods such as probe sonication, micro-fluidisation and high pressure homogenisation. The 
therapeutic agents in NPs could be dissolved, encapsulated within or adsorbed onto the constituent 
polymer matrix.  
 
 
Figure 8: A schematic illustration of a) nanosphere showing how drug (small spheres) is dispersed throughout the polymer 
matrix and b) nanocapsule in which drug is confined in a reservoir bound by single membrane. 
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Depending on the processing method utilized, the resulting structure could either be nanosphere in 
which the active agent is dispersed throughout a polymeric matrix system in the particle or as a 
nanocapsule in which the drug exist in a vesicular reservoir enclosed by single polymeric  membrane 
(Letchford and Burt, 2007). Nanoparticles, due to their ability to overcome physiological barriers while 
delivering drug molecules to specific cells or tissue compartments either by passive or ligand mediated 
movements make them a highly versatile class of drug delivery systems (Mallipeddi and Rohan, 2010). 
NPs have demonstrated promising prospects for superior drug delivery, especially in the area of cancer 
pharmacotherapy (Prabhu, Patravale and Joshi, 2015) and this novel approach could be extended into 
the area of HIV prevention. Targeted delivery of microbicide drugs into vaginal tissues through the use 
of nanoparticles has recently been developed to overcome issues such as drug movement across mucosa 
barriers, physicochemical stability, solubility, and immunogenic response typically associated with 
conventional hydrogel formulations (Rohan and Sassi, 2009). If microbicides are to offer the necessary 
protection against HIV infection, it will be crucial for the active components of the formulation to 
navigate the many barriers in order to reach the specific site for optimal antiviral activity. Nanoparticles, 
when employed as carrier systems could aid the delivery of active drug to these sites. Surface engineered 
dapirivine-loaded polycaprolactone nanoparticles have been demonstrated to have the potential to 
facilitate movement of the antiviral drug across mucosa barriers in the cervico-vaginal region (das 
Neves et al., 2012). Furthermore, microbicide formulations delivering active drug through nanoparticles 
have been confirmed to exhibit better antiviral activity due to increased intracellular drug delivery 
facilitated by better cellular uptake of the drug loaded nanoparticles (das Neves et al., 2012).  
In addition to enhancing antiviral activity through more efficient drug transport across barriers and 
better cellular uptake, nanoparticles can be instrumental in improving the acceptability and use of 
microbicides when their potential to protect active agents from untimely metabolism are applied to 
prolonging microbicidal activities.  A poly (D,L-lactide-co-glycolide) nanoparticle delivering the highly 
potent anti-HIV protein PSC-RANTES was shown to offer superior antiviral activity over an extended 
period, thus confirming the prospects of achieving longer acting microbicide action when active drugs 
are presented in nanoparticle carrier systems (Ham, Cost, Sassi, Dezzutti and Rohan, 2009). Some 
pioneering and innovative work in utilising nanoparticles to interfere with HIV infectivity is currently 
underway. Melittin, a cytolytic peptide component of bee venom, incorporated into shells of 
perfluorocarbon nanoparticles has been proven to inhibit HIV infectivity by disrupting lipid viral 
envelopes and at the same time being safe and actually therapeutic for host cells (Hood, Jallouk, 
Campbell, Ratner and Wickline, 2013; Jallouk et al., 2014). Chitosan nanoparticles containing tenofovir 
with exceptional mucoadhesive properties are also being developed to target mucosa reservoirs of HIV 
in areas such as the vaginal epithelial tissues (Meng, Sturgis and Youan, 2011) Some of these positive 
developments strengthen arguments that nanotechnology offers immense opportunities for developing 
ideal microbicides in the near future. 
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3.3.3 Dendrimers for microbicides 
Dendrimers are highly branched and usually symmetrical three dimensional structures with a well-
defined architecture where peripheral groups are joined to the core by branching units (Murugavel, 
2014). They are classified as supramolecular (Astruc, Boisselier and Ornelas, 2010) in that they are 
typically a chemical system made up of a discrete number of assembled subunits rather than a single 
unit (Lehn, 1988, 1995). Dendritic molecules can be visualized as repetitive layers of multifunctional 
blocks of a protected and unprotected scheme of complimentary monomers typically resulting in a 
fractal-like tree in which each incorporated layer serves as a platform for the successive layer (Tomalia 
and Cheng, 2012). The first completely characterized repetitively branched and polyfuctional molecule 
was generated by Vogtle et al. in 1978 from a protocol based on cycles of nucleophile amine addition 
to electron-poor cyanoalkene, followed by reduction of the cyano groups which in turn yields new 
amine moieties for further reactions (Buhleier, Wehner and Vögtle, 1978). Several other contributions 
like Vogtle’s, particularly those form the research groups of Newkome, Denkwalter and Tomalia 
(Denkewalter, Kolc and Lukasavage, 1982; Newkome, Yao, Baker and Gupta, 1985; Tomalia et al., 
1985) build upon experiments setting out some fundamental principles of molecular organisation 
pioneered by P.J Flory in the middle of the twentieth century (Flory, 1942)     
Extensive research into the possible applications of dendrimers in diverse areas within the biological 
and medical fields is currently ongoing (Caron et al., 2010; Mintzer and Grinstaff, 2011; Nasibullah, 
Hassan, Ahmad, Khan and Rahman, 2013; Noriega-Luna et al., 2014). Some properties of dendrimers 
including their nanoscopic size and uniformity, flexible molecular structure and presence of multiple 
peripheral functional groups to facilitate conjugate formation with a wide range of drug molecules make 
dendrimers highly suited for targeted delivery of drugs (Kesharwani, Jain and Jain, 2014), and hence 
the rigorous investigations into their potential as drug delivery systems, especially in the area of cancer 
pharmacotherapy and delivery of macromolecules (Brannon-Peppas and Blanchette, 2012; Cheng, 
Zhao, Li and Xu, 2011; Lim and Simanek, 2012; Parhi et al., 2012; Parveen, Misra and Sahoo, 2012). 
Furthermore, the unique architecture of dendritic molecules, especially that of its interior with enough 
void volume makes it ideal for doping with a wide range of molecules for desirable functioning 
(Tomalia and Cheng, 2012). Presently, drug-dendrimer conjugates of anticancer drugs including 
Fluorouracil, Methotrexate, Doxorubicin, Paclitaxel, Camptotecin and a few more are being 
investigated for improved physical attributes and performance. In addition to anticancer drugs, several 
other classes of medicines including anti-inflammatory and antimicrobial agents are being investigated 
for presentation as drug-dendrimer units (Tomalia and Cheng, 2012).  
The attractive characteristics of dendrimers are being utilized for the development of safer and more 
efficient microbicides. First of all, dendrimers by themselves can be inherently antiretroviral when some 
functional groups capable of interfering with viral adhesion to cells are incorporated onto their surface 
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during synthesis (Jiménez et al., 2012). Some functional groups designed to confer anti-HIV activity on 
certain classes of dendrimers are shown in Table 3. Proteins present on surface of viruses bind multiple 
carbohydrates on target host cells during invasion (Gajbhiye, Palanirajan, Tekade and Jain, 2009). 
Groups similar to these carbohydrates on host cell surfaces can be incorporated onto dendrimers 
peripheries to act as preferred receptors for invading viruses thus sparing host cells and therefore 
preventing infection. These have been successfully tested with some influenza viruses and the principle 
can be explored for the synthesis of dendrimers to be used as microbicides (Roy, 1996; Tsvetkov et al., 
2002). 
  
 
Figure 9: Schematic illustration of dendrimer showing the core (G0) and branching points (G1 – G4) which serve as platforms 
for either expanding the network of molecules with more basic units (dendron) or with different functional groups for a specific 
activity (Illustration based on design by Oleg Lukin; obtained from Wikimedia Commons) 
 
In addition to preventing viral binding to host cells, polyanionic dendrimers have been shown to affect 
the life cycle of viruses, including HIV (Tephly, 1991). Carboxylated fullerene-based dendrimers for 
instance is known to inhibit viral protease and reverse transcriptase in acutely HIV infected primary 
human lymphocytes (Yoshida et al., 2013). The molecular structure of dendrimers, apart from allowing 
the incorporation of specific functional groups to confer antiviral capabilities also facilitates the 
conjugation of other antiretroviral compound for possible multi-targeted activities against the 
transmission of viruses. Two of the most widely studied antiretroviral for microbicide development, 
tenofovir (TFV) and maraviroc (MVR) are reported to have been successfully conjugated onto 
polyanionic carbosilane dendrimers in separate formulations (Sepúlveda-Crespo, Gómez, De La Mata, 
Jiménez and Muñoz-Fernández, 2015). Formulations combining two different dendrimers to be used as 
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microbicides have also been reported (Sepúlveda-Crespo et al., 2014). In both dendrimer-dendrimer 
and dendrimer-drug combinations, where lower overall concentrations offered greater antiviral activity 
than usually seen in monotherapies, a case for using a combination formulation to offer optimal activity 
from low doses for minimal incidence of toxicity and emergence of resistant viral strain has firmly been 
established (das Neves et al., 2012).  
  
Table 3: Chemical groups used in modification of some classical dendrimers for enhanced antiviral activity against HIV 
Dendrimer type 
[Code name of specific 
compound and reference] 
Functional group delivering anti-HIV 
activity 
Site and mode of anti-HIV 
activity 
Polyamidoamine (PAMAM) 
 
[BRI2932 (Witvrouw et al., 
2000)] 
  
 
Attaches to gp120 to inhibit 
binding to MT-4 cells  
 
 
 
 
 
Polyamidoamine (PAMAM) 
 
[BRI6195 (Witvrouw et al., 
2000)] 
 
 
 
 
Attaches to gp120 to inhibit 
binding to MT-4 cells and 
capable of permeating host 
cell to inhibit reverse 
transcriptase and integrase 
activities during replication 
 
Gallic acid-triethylene glycol 
(GATG) 
 
[[G1]-CO2Na (Doménech et 
al., 2010)] 
 
 
 
Complexes with C-terminal 
domain of viral capsid protein 
which results in disruption of 
capsid assembly for 
maturation of HIV type 1  
Carbosilane 
 
[2G-S16 (Chonco et al., 2012)] 
 
 
 
Combines with both gp120 
on viral surface and CD4 on 
host cells to disrupt fusion of 
virus onto host cell 
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Irritations, possible epithelial injury and inflammation from local application of microbicides have 
emerged as serious concerns (Beer et al., 2006; Buckheit and Buckheit Jr., 2012). It is therefore 
encouraging to learn that many dendrimer-based microbicides currently in development appear to be 
less irritant to the mucosa environment where their application is intended. Following the formulation 
and evaluation of polyanionic carbosilane dendrimers G3-S16 and G2-NF1, it was observed that in 
addition to blocking the entry of HIV into target host cell, these dendrimers protected the epithelial 
layer from cell disruption. Furthermore, these dendrimers did not induce any inflammatory cytokines 
or caused an irritation or vaginal lesion upon application (Córdoba et al., 2013).  
 A similar observation of biocompatibility and encouraging antiviral activity was recorded when water-
soluble anionic carbosilane dendrimer (2G-S16) was studied (Chonco et al., 2012) confirming the 
consistent safety profile among these kind of dendrimers when employed as microbicides. The activity 
and safety profiles of dendrimer based formulations has so far been promising. The nano-range 
microbicide which is furthest in the development phases, dendrimer based Vivagel® (Starpharma, 
Melbourne, Australia) performed well on safety and efficacy at preliminary animal testing and  
progressing into human trials (Roy et al., 2015). Phase I clinical trials have been completed with some 
favourable general outcomes though further progression seems to have been halted because of excessive 
inflammation and damage to epithelial tissue (McGowan et al., 2011; Moscicki et al., 2012). It has been 
observed though that current nanotechnology being explored for microbicide formulation is shifting 
from utilising inherent antiviral activity of the nanostructures to using them as systems to deliver highly 
active antiretroviral drugs (das Neves, Amiji, Bahia and Sarmento, 2010). Therefore the prospects of 
utilising the flexible structure of dendrimers to deliver active drug for prevention of HIV transmission 
remains positive and worth considering.  
As outcomes from clinical trials on conventional formulations of microbicides has largely been negative 
(Grant et al., 2008), shifting our focus onto nanostructures such as dendrimers in pursuit of an ideal 
microbicide seem to be a step in the right direction.      
 
3.3.4 Liposomal microbicide 
Liposomes, from a Greek root word meaning ‘fat body’ is a multi-layered phospholipid structure with 
a hollow core, the inner portion usually made of a polar phosphate group and the outer consisting of 
one or more bilayers of natural or synthetic lipids (Watwe and Bellare, 1995). Liposomes made of 
natural phospholipids are physiologically inert, weakly immunogenic and of low toxicity (Immordino, 
Dosio and Cattel, 2006). Furthermore, due to their combined hydrophilic and lipophilic nature, a wide 
range of drugs with different lipophilicities can be effectively encapsulated within liposomes, the highly 
hydrophilic ones staying in the polar compartment, the lipophilic ones in the lipid layers and those with 
intermediate partition coefficients easily apportioning between the polar and lipid portions of the 
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liposome (Gulati, Grover, Singh and Singh, 1998). The applicability of liposomes have been further 
enhanced recently due to a steady progression from conventional liposomes to a new generation of 
liposomes developed through modulation of lipid constituents, size and charge adjustments and surface 
modification (Torchilin, 2005). Structurally, the lipid microenvironment of some newer generations of 
liposomes, the so-called lipid raft achievable from peculiar lipid composition utilising 
glycosphingolipids (GSLs), sphingomyelins and cholesterols make them capable of serving as 
platforms of membrane with associated activities such as signal transduction, cell adhesion and 
lipid/protein organisation, thus increasing their appeal for biomedical applications (Anderson and 
Jacobson, 2002; de Gassart, Geminard, Fevrier, Raposo and Vidal, 2003; Helms and Zurzolo, 2004) 
These physical characteristics of liposomes and their widening applicability due to their continuous 
improvement make them very attractive for consideration as delivery systems, especially in cases where 
drug solubility is an issue. With regards to microbicide activity against HIV transmission in the vagina, 
some potential challenges are anticipated. In order to inhibit activities of viruses that have broken 
through the physical barrier provided by microbes, active drug, ideally in nano delivery systems, 
capable of matching the ease with which viruses travel through epithelial layers to infect cells would be 
required to inhibit viral activity either at point of entry or within tissues (Pope and Haase, 2003; Vanić 
and Škalko-Basnet, 2013). Furthermore, the carrier system delivering the active drug ought to have 
minimal interference with vaginal flora and pH, minimal irritation to the mucosa as well as being 
effective in protecting the drug from sudden changes in the vaginal environment e.g. vaginal fluids due 
to arousal and release of semen (Vanić and Škalko-Basnet, 2013). 
          
Figure 10: Schematic representation of a) Liposome showing assembly of phospholipids in a bilayer that yields both aqueous 
and lipid compartments within the structure and b) various forms of lamellar and sizes; small unilamellar vesicles (SUV), large 
unilamellar vesicles (LUV), giant unilamellar vesicles (GUV), multilamella and multivesicular (van Swaay, 2013) 
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Studies looking into the potential of liposomes as delivery systems for microbicides and capable of 
meeting these requirements have reported some optimistic outcomes indicating that these 
nanostructures could be the future of effective microbicides. The membrane-like characteristics of 
liposomes are also thought to have a potential of fusion with viron material, thus giving these structures 
some possibility of interfering with HIV transmission by competing with host membrane for uptake of 
the virus. Several liposomal membranes based on their lipid composition have been assessed for the 
potential of fusion with HIV-1 virus and found to be in the order cardiolipin (CL) > > 
phosphatidylinositol > CL/dioleoylphosphatidylcholine (DOPC) (3: 7), phosphatidic acid > 
phosphatidylserine (PS), PS/cholesterol (2:1) > PS/PC (1:1), PS/phosphatidylethanolamine (1:1) > 
DOPC, erythrocyte ghosts (Larsen et al., 1993; Malavia et al., 2011). 
In a study evaluating a liposome formulation of MC-1220, a highly potent and selective non-nucleoside 
reverse transcriptase inhibitor (NNRTI) on the prevention of HIV transmission through the vagina of 
non-human primate models (Caron et al., 2010), it was found that formulating MC-1220 in a liposomal 
gel allowed high amount of drug loading in a small volume of formulation, thus solving some of the 
bioavailability issues typically seen in conventional gel formulations (Loftsson and Masson, 2001). In 
addition, the liposomal formulations of the NNRTI were seen to be less irritating to mucosa tissues. 
Finally and most importantly, it was observed that the liposomal formulation offered some protection 
against viral transmission and in fact reduced the viral load in infected models.  
Another work that investigated the feasibility of liposomes for use as microbicides (Wang et al., 2012) 
utilized octylglycerol (OG), a synthetic lipid derived from human breastmilk and has been shown to 
destabilize viral envelopes and therefore a potential microbicide (Isaacs, 2001; Isaacs and Thormar, 
1991; Skinner et al., 2010). In this study, liposomes were produced from combinations of OG and 
phosphatidyl choline in ratios that ensured in vitro antiviral activity and at the same time sparing the 
natural vaginal flora. Activities of the liposomes were compared to two conventional gel formulations. 
 
3.3.5 RNA interference (RNAi) as strategy for microbicidal action 
RNA interference (RNAi) is described as a post-translational and post-transcriptional inhibition of gene 
expression typically brought about by destruction of specific RNA molecules and this biological process 
has been demonstrated as capable of preventing HIV transcription, thus having some promising 
prospects in the prevention of viruses infecting host cells (Lee et al., 2002; Zhang et al., 2006). With 
regards to preventing HIV transmission through microbicidal action in the female reproductive mucosa, 
some pioneering work utilising small-interfering RNA (siRNA) densely packed into biodegradable 
polymer nanoparticles have been used to bring about silencing of endogenous genes in the genital track, 
ultimately resulting in protection against challenge from the infectious pathogens (Woodrow et al., 
2009). In another study detailing the impact of siRNA on viral transmission, vaginal instillation of 
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siRNA targeting Herpes Simplex virus 2 (HSV2), an important cofactor in HIV transmission was 
confirmed to reduce overall lethal viral challenge in mice thus suggesting siRNAs as an important and 
a suitable component of microbicide formulation (Palliser et al., 2006). Outcomes from these studies 
and several others have established RNA interference firmly as a strategy for preventing viral infections 
and hence siRNAs as valuable components for the development of future microbicides. However, a 
massive challenge remains with delivery of siRNAs as these structures are highly unstable in serums 
and delivery across cell membranes. Delivery strategies showing promise so far, such as liposomal, 
viral or nanoparticle delivery are heavily reliant on nanotechnology and therefore adds to the compelling 
case being made for utilising nanotechnology for developing  the next generation of microbicides 
(Nguyen, Menocal, Harborth and Fruehauf, 2008). The future of RNA interference as a strategy for 
disease cure and prevention is promising and this is attested by the vibrant pharmaceutical companies’ 
involvement in research currently ongoing in this field, especially with regards to delivery of these 
nucleic acids  
 
3.4 Current challenges with nanotechnology 
Findings from critical examination of literature regarding microbicide development supports the need 
for a different approach to this venture if better outcomes than we have seen in the last few decades is 
desired. And this review has so far made a strong case for utilising tools presented by nanotechnology 
as various studies continue to demonstrate the possibility of deriving more effective microbicides when 
nanostructures are employed in their delivery. Notwithstanding the numerous benefits we stand to gain 
along this path, there are some critical challenges presently confronting the use of nanostructures for 
therapeutic interventions. The first and perhaps the most important of these concerns is the biosafety of 
nanoparticles. Indeed materials with widely varying degradation times and chemical compositions are 
already being either used or currently being employed as nanostructures for pharmacotherapy. But since 
these have only been recently used, knowledge about their long term effect on consumers are lacking 
(Jiang, Kim, Rutka and Chan, 2007). Furthermore, methods used in assessing toxicological hazards in 
conventional medicines may not necessarily be useful for nanostructures as this class of therapeutics 
may have entirely different surface and physico-chemical properties dictated by their extremely small 
size (De Jong and Borm, 2008). However, more recent work on generation of nanofibers has been 
directed at uncovering processes which can be scaled up in a manufacturing sense (Brako, Raimi-
Abraham, Mahalingam, Craig and Edirisinghe, 2015)  
The second of the most relevant challenges facing the development of nanotech based therapies is our 
current inability to produce commercial quantities of these fantastic nanostructures that have been 
demonstrated to positively impact the future of microbicide. Most of the nanotech based development 
strategies outlined in this review are still largely functional only on a laboratory scale and bridging the 
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gap in order to produce commercial quantities to consolidate gains so far made remain elusive (Beyer 
et al., 2015). 
For the revolution in microbicide development by nanotechnology to be sustainable, these two key 
challenges – biosafety and upscaling of production challenges ought to be addressed in efforts to move 
any obstacles that may impede progress in the near future. Fortunately, a strong and rapidly emerging 
field of study and research, nanotoxicology promises to deliver fit-for-purpose tools and concepts in 
assessing the safety of therapeutic nanostructures and mitigating their immediate and long term impact 
among consumers (Shvedova, Pietroiusti and Kagan, 2016). With respect to producing commercial 
quantities of nanostructures for drug delivery, it is our hope and recommendation that as much efforts 
as dedicated to designing prototypes of these structures will be invested in finding various means of 
bridging the gap currently existing between laboratory and industrial level quantities to facilitate the 
movement of these innovative products into market.       
 
4. Perspective 
For over three decades, substantial challenges yet to be surmounted has kept humans from developing 
an ideal microbicide capable of preventing HIV transmission in the safest possible manner. For a 
microbicide to effectively deliver the protection expected, highly complex multi-level biochemical 
interaction among the host, virus and the drug would have to occur. Some details in these interaction 
remain unknown but recent efforts in establishing a framework for advancing knowledge required for 
developing microbicides has improved our understanding of the subject and has actually been translated 
into practical methodological approaches that are bringing us closer to achieving a suitable microbicide 
(Hendrix et al., 2009).  
This review has looked into some of the obstacles encountered in developing a suitable microbicide, 
mainly from the formulation point of view. A strong case has been made for taking on new formulation 
approaches such us exploring the many options available in the area of nanotechnology. 
Nanotechnology has brought about extensive improvement in some therapeutic areas like cancer 
management and replicating some of these success stories in the area of HIV prevention is very likely 
considering preliminary outcomes from projects looking into formulating microbicides using 
nanotechnology concepts. 
Aside formulation challenges, microbicide development appear to have been negatively affected by the 
lack of political enablement and incentives that otherwise would have made this an attractive venture 
for the big pharmaceutical establishments to get involved (Grant et al., 2008). It has been argued that 
no major pharmaceutical company as yet has been involved in efforts to develop microbicides and most 
probably due to the lack of liability protection including government supported insurance which is 
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typically made available for pharmaceutical organisations involved in the development of preventive 
medications such as vaccines (Grant et al., 2008). Sadly, this has left the development of microbicides 
to nongovernmental organisations, some governmental agencies and academic scientists who rarely 
have the necessary experience in drug development. Therefore moving into the future of microbicide 
development, new policies guaranteeing incentives and protection for investors in the developing of 
microbicides could attract the needed expertise into this area and ensure a timely development of an 
ideal microbicide. 
Output from microbicide development, considering the amount of effort, resources and time invested 
in the venture to date, leaves much to be desired. A key reason for this poor output is failure in 
translating scientifically sound concepts into products useful in the real world. It must be appreciated 
that not every scientific concept will do well in real life as there are some present challenges practically 
unsurmountable (Klasse, Shattock and Moore, 2006). Therefore in order to improve the success rate of 
microbicide development, a robust model capable of subjecting concepts and drug candidates to 
rigorous preclinical assessment and offering an effective screening in order to accurately predict 
concepts capable of working in the real world ought to be developed. The normal preclinical protocols 
for pre-assessment of conventional formulations may not be enough for predicting the success of 
microbicide formulation considering the complex mix of requirements, including efficacy, safety, 
tolerability and acceptability needed for a microbicide to function properly. Such a robust model for 
predicting microbicide development success would be useful for managing the already inadequate time, 
resources and expertise needed to bring about an ideal microbicide. 
By way of conclusion, there are diverse views on the best route to obtaining a microbicide which is safe 
and convenient to use, effective in protecting users from HIV infection and affordable enough to allow 
usage in order to bring about the wider public health gains they are intended for. But what all 
stakeholders agree is continuing efforts and even stepping up our commitment in developing an 
accessible, affordable and effective microbicide which could drive a preventive strategy to ensure a 
drastic reduction in new HIV infections.    
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